Home » Stocks » IRIX

IRIDEX Corporation (IRIX)

Stock Price: $4.93 USD -0.46 (-8.53%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $5.09 +0.16 (3.25%) Jan 22, 7:43 PM
Market Cap 68.52M
Revenue (ttm) 35.81M
Net Income (ttm) -7.71M
Shares Out 13.89M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $4.93
Previous Close $5.39
Change ($) -0.46
Change (%) -8.53%
Day's Open 5.28
Day's Range 4.88 - 5.54
Day's Volume 308,129
52-Week Range 1.40 - 5.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

MOUNTAIN VIEW, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary unaudited operational and financial results for the fourth quarter and ful...

Seeking Alpha - 1 week ago

Iridex Corp. seems to be at the initial stage of a growth inflection that could drive the stock up 175-625%. IRIX has a commercial product which could revolutionize glaucoma treatment, with an...

GlobeNewsWire - 1 month ago

MOUNTAIN VIEW, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and r...

Seeking Alpha - 2 months ago

IRIDEX's (IRIX) CEO Dave Bruce on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Iridex (IRIX) delivered earnings and revenue surprises of 33.33% and 13.08%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

MOUNTAIN VIEW, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 26, 2020.

Benzinga - 2 months ago

Iridex (NASDAQ: IRIX) unveils its next round of earnings this Monday, November 09. Get prepared with Benzinga's ultimate preview for Iridex's Q3 earnings.

GlobeNewsWire - 2 months ago

MOUNTAIN VIEW, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the upcoming Stifel Virtual Healthcare Conference.

Zacks Investment Research - 2 months ago

Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

MOUNTAIN VIEW, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the third quarter of 2020 after the cl...

Seeking Alpha - 5 months ago

IRIDEX's (IRIX) CEO Dave Bruce on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha - 5 months ago

Iridex Corporation: Deserves More Patience Given Shift In Commercial Strategy And Aggressive Cost Cutting

GlobeNewsWire - 5 months ago

MOUNTAIN VIEW, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 27, 2020.

Zacks Investment Research - 5 months ago

Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 6 months ago

MOUNTAIN VIEW, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter of 2020 after the...

Seeking Alpha - 8 months ago

IRIDEX Corporation (IRIX) CEO David Bruce on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Iridex (IRIX) delivered earnings and revenue surprises of 29.41% and -5.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 9 months ago

Names Prior CFO/COO as Interim CFO Names Prior CFO/COO as Interim CFO

Seeking Alpha - 10 months ago

IRIDEX Corp (IRIX) CEO David Bruce on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Iridex (IRIX) delivered earnings and revenue surprises of 31.25% and 0.53%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

IRIDEX Corp (IRIX) CEO David Bruce on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

MOUNTAIN VIEW, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the appointment of Robert Gunst as Chairman of the Board, effective October 23, 201...

GlobeNewsWire - 1 year ago

MOUNTAIN VIEW, Calif., Sept. 11, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma an...

Zacks Investment Research - 1 year ago

Laser Systems & Components Industry Outlook: Prospects Bright

Other stocks mentioned: CUTR, LITE
Zacks Investment Research - 1 year ago

Iridex (IRIX) delivered earnings and revenue surprises of 18.18% and -4.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

IRIDEX Corp (IRIX) CEO William Moore on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Iridex (IRIX) delivered earnings and revenue surprises of 8.33% and 1.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

About IRIX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems tha... [Read more...]

Industry
Medical Devices
IPO Date
Feb 15, 1996
CEO
David I. Bruce
Employees
94
Stock Exchange
NASDAQ
Ticker Symbol
IRIX
Full Company Profile

Financial Performance

In 2019, IRIX's revenue was $43.45 million, an increase of 1.99% compared to the previous year's $42.60 million. Losses were -$8.81 million, -31.22% less than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for IRIX stock is "Buy." The 12-month stock price forecast is 6.50, which is an increase of 31.85% from the latest price.

Price Target
$6.50
(31.85% upside)
Analyst Consensus: Buy